Response by Hu Et Al to Letter Regarding Article, “impact of the 2017 ACC/AHA Guideline for High Blood Pressure on Evaluating Gestational Hypertension–Associated Risks for Newborns and Mothers: A Retrospective Birth Cohort Study”
Jie Hu,Yuanyuan Li,Kathryn M Rexrode,Shunqing Xu
DOI: https://doi.org/10.1161/circresaha.119.316371
IF: 23.213
2020-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 126, No. 1Response by Hu et al to Letter Regarding Article, “Impact of the 2017 ACC/AHA Guideline for High Blood Pressure on Evaluating Gestational Hypertension–Associated Risks for Newborns and Mothers: A Retrospective Birth Cohort Study” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse by Hu et al to Letter Regarding Article, “Impact of the 2017 ACC/AHA Guideline for High Blood Pressure on Evaluating Gestational Hypertension–Associated Risks for Newborns and Mothers: A Retrospective Birth Cohort Study” Jie Hu, Yuanyuan Li, Kathryn M. Rexrode and Shunqing Xu Jie HuJie Hu From the Key Laboratory of Environment and Health (HUST), Ministry of Education and Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (J.H., Y.L., S.X.) Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (J.H., K.M.R.). Search for more papers by this author , Yuanyuan LiYuanyuan Li From the Key Laboratory of Environment and Health (HUST), Ministry of Education and Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (J.H., Y.L., S.X.) Search for more papers by this author , Kathryn M. RexrodeKathryn M. Rexrode Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (J.H., K.M.R.). Search for more papers by this author and Shunqing XuShunqing Xu From the Key Laboratory of Environment and Health (HUST), Ministry of Education and Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (J.H., Y.L., S.X.) Search for more papers by this author Originally published2 Jan 2020https://doi.org/10.1161/CIRCRESAHA.119.316371Circulation Research. 2020;126:e5–e6In Response:We appreciate the interest of Roberts et al in our article about the potential impact of adopting the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guidelines in prenatal care on maternal and neonatal health.1 We agree that the observed associations between stage 1 gestational hypertension (systolic/diastolic blood pressure 130–139/80–89 mm Hg) and risk of adverse birth outcomes were relatively small, but stronger associations were observed for stage 2 gestational hypertension (≥140/90 mm Hg). Additionally, we did not have data available to determine whether a preterm or early term delivery was spontaneous or medically indicated; other studies with available data should address this issue. Furthermore, in a subset of 6520 women with available data on laboratory blood tests, we observed that stage 1 gestational hypertension was associated with statistically significant, but relatively small, alterations in most of the indicators for liver, kidney, and coagulation functions; these findings may indicate potential impact of stage 1 gestational hypertension on maternal health during pregnancy at the population level, but the clinical implication is still unclear and deserves further investigation.One of the novel findings of our study was that gestational elevated blood pressure (120–129/<80 mm Hg), the subclinical blood pressure elevation defined by the 2017 ACC/AHA hypertension guidelines,2,3 was not associated with increased risk of adverse birth outcomes or altered markers of maternal liver, kidney, and coagulation function. In contrast, gestational prehypertension (120–139/80–89 mm Hg), the subclinical blood pressure elevation defined by the previous hypertension guidelines,4 has been associated with increased risk of adverse birth outcomes in several previous studies.5,6 Therefore, our findings suggest potential improvements in the detection of blood pressure elevations during pregnancy if the 2017 ACC/AHA hypertension guidelines were adopted to define gestational hypertension. To our knowledge, our study is the first study to estimate the impact of adopting the new hypertension guidelines on perinatal health. More studies are needed to replicate our findings, especially in participants with diverse backgrounds (eg, race/ethnicity, socioeconomic status, and health conditions).If the 2017 ACC/AHA hypertension guidelines were adopted in prenatal care to define gestational hypertension, a large number of women would be labeled as having gestational hypertension, and most of them would be within the stage 1 hypertension range, which would lead to an increase in medical costs because of potential increases in surveillances and interventions. But the risk and benefit of changing the diagnostic criteria and management strategies of gestational hypertension remain unknown and need further investigation. The latest Practice Bulletin from the American College of Obstetricians and Gynecologists acknowledged the uncertainty regarding the impact of adopting the 2017 ACC/AHA hypertension guidelines in prenatal care on maternal and neonatal health and indicated that the management strategies for gestational hypertension within the stage 1 hypertension range were still unknown.7 Because of the absence of supporting evidence, the Practice Bulletin did not change diagnostic criteria for gestational hypertension or provide recommendations for management strategies of stage 1 gestational hypertension. The ongoing randomized clinical trial, Chronic Hypertension and Pregnancy Project (URL: https://clinicaltrials.gov/ct2/show/NCT02299414. Unique identifier: NCT02299414), is designed to evaluate the effectiveness and safety of lowering the antihypertensive treatment target for blood pressure elevations during pregnancy. Findings from this trial could provide novel and timely evidence on the optimal treatment target and management strategies for high blood pressure during pregnancy. Nevertheless, the cost-benefit ratio for changing the diagnostic threshold and treatment target for gestational hypertension requires systematic research.DisclosuresNone.FootnotesFor Disclosures, see page e6.References1. Hu J, Li Y, Zhang B, Zheng T, Li J, Peng Y, Zhou A, Buka SL, Liu S, Zhang Y, et al. Impact of the 2017 acc/aha guideline for high blood pressure on evaluating gestational hypertension-associated risks for newborns and mothers.Circ Res. 2019; 125:184–194. doi: 10.1161/CIRCRESAHA.119.314682LinkGoogle Scholar2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol. 2018; 71:e127–e248.CrossrefMedlineGoogle Scholar3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.Hypertension. 2018; 71:e13–e115.doi: 10.1161/HYP.0000000000000080LinkGoogle Scholar4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report.JAMA. 2003; 289:2560–2572. doi: 10.1001/jama.289.19.2560CrossrefMedlineGoogle Scholar5. Fukushima K, Morokuma S, Tsukimori K, Murata M, Wake N. Blood pressure measurements within the JNC7 pre-hypertensive range after 32 weeks of gestation are a risk factor for decreased fetal growth.Hypertens Res. 2012; 35:128–130. doi: 10.1038/hr.2011.158CrossrefMedlineGoogle Scholar6. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: Case-control study.BMJ. 2001; 322:1089–1093; discussion 1093-1084CrossrefMedlineGoogle Scholar7. American College of Obstetricians and Gynecologists. ACOG practice bulletin No. 203: chronic hypertension in pregnancy.Obstet Gynecol. 2019; 133:e26–e50. doi: 10.1097/AOG.0000000000003020CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails January 3, 2020Vol 126, Issue 1 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.119.316371PMID: 31895664 Originally publishedJanuary 2, 2020 PDF download Advertisement